Virios therapeutics regains compliance with nasdaq minimum bid price requirement

Atlanta, may 25, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on the nasdaq capital market.
VIRI Ratings Summary
VIRI Quant Ranking